SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

Apimeds Pharmaceuticals US Reports Third Quarter 2026 Results, Delivers First Operating Revenue from Technology Services

Quarterly revenue of $2.89 million and operating income of $2.0 million as the company completes its transition to a technology infrastructure businessMATAWAN, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- via IBN — Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), toda…

APUS

Related stories